학술논문
FDA Safety Warning on the Cardiac Effects of Lamotrigine: An Advisory From the Ad Hoc ILAE/AES Task Force.
Document Type
Article
Author
Source
Subject
*LAMOTRIGINE
*EPILEPSY
*TASK forces
*ARRHYTHMOGENIC right ventricular dysplasia
*MEDICAL personnel
*CARDIAC patients
*HEART failure
*
*
*
*
*
*
Language
ISSN
1535-7597
Abstract
The International League Against Epilepsy (ILAE)/American Epilepsy Society (AES) Task Force on the cardiac effects of lamotrigine was convened in response to a recent addition to the lamotrigine label by the US Food and Drug Administration (FDA).[1] Lamotrigine is the nonproprietary name for a medicine that is sold under its generic name and several brand names including Lamictal™. Nonspecific EKG abnormalities (eg, nonspecific ST and T wave abnormalities) are not concerning, and should not preclude these individuals from being prescribed lamotrigine. Are These Warnings and Precautions Only Relevant to Lamotrigine or Are They Also Applicable f... The cardiac concerns stem from lamotrigine's sodium channel blocking properties. [Extracted from the article]